BSEM (BioStem Technologies) Long-Term Debt: $0.0 Mil (As of Sep. 2025)


BSEM BioStem Technologies Inc BSEM
49 GF Score
Price $3.26
GF Value $142.68
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioStem Technologies Long-Term Debt?

BioStem Technologies BSEM -0.76% 49 Long-Term Debt is $0.0 Mil as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $142.68 (Possible Value Trap). The stock has 3 warning signs investors should review.

BioStem Technologies's Long-Term Debt for the quarter that ended in Sep. 2025 was $0.0 Mil.

BioStem Technologies's quarterly Long-Term Debt stayed the same from Sep. 2024 ($0.2 Mil) to Dec. 2024 ($0.2 Mil) but then declined from Dec. 2024 ($0.2 Mil) to Sep. 2025 ($0.0 Mil).

BioStem Technologies's annual Long-Term Debt declined from Dec. 2022 ($1.0 Mil) to Dec. 2023 ($0.3 Mil) and declined from Dec. 2023 ($0.3 Mil) to Dec. 2024 ($0.2 Mil).

BioStem Technologies  (OTCPK:BSEM) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BioStem Technologies Long-Term Debt Related Terms

BioStem Technologies Long-Term Debt Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Long-Term Debt Chart

BioStem Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.67 1.80 1.03 0.27 0.15

BioStem Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Sep24 Dec24 Sep25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.41 0.27 0.15 0.15 0.00
BSEM
49GF Score
BioStem Technologies Inc BSEM
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.0 Mil mean?
BioStem Technologies (BSEM) has a Long-Term Debt of $0.0 Mil as of Sep. 2025.
Is BioStem Technologies' Long-Term Debt too high?
BioStem Technologies' current Long-Term Debt is $0.0 Mil. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Long-Term Debt compare to XLO and TCRX?
BioStem Technologies' Long-Term Debt of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. BioStem Technologies's current Long-Term Debt is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $142.68, compared to a current price of $3.26 — trading 97.7% below its estimated fair value. The current Long-Term Debt is $0.0 Mil. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Long-Term Debt is $0.0 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioStem Technologies (BSEM) Overvalued in 2026?

Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued. The current stock price of $3.26 is trading 97.7% below its estimated GF Value™ of $142.68. GuruFocus considers BioStem Technologies to be Possible Value Trap.

Key valuation signals for BSEM:

  • Long-Term Debt: $0.0 Mil
  • GF Value™: $142.68 vs. price of $3.26 (97.7% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioStem Technologies Business Description

Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score

Get the complete analysis for BSEM

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.26
Price
$142.68
GF Value